Clinical presentation and staging of Hodgkin lymphoma

Seminars in Hematology

Volumn 53, Issue 3, 2016, Pages 148-154

  Gallamini, Andrea ^a   Hutchings, Martin ^b   Ramadan, Safaa ^c,d  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b University of Copenhagen   (Denmark)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d CAIRO UNIVERSITY   (Egypt)

Author keywords

Hodgkin lymphoma; PET; Presentation; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

BONE MARROW BIOPSY; CANCER RISK; CANCER STAGING; CELL METABOLISM; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; GLYCOLYSIS; HODGKIN DISEASE; HUMAN; IMMUNOPATHOLOGY; MEDICAL HISTORY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; SYMPTOM; TUMOR VOLUME; BIOPSY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; X-RAY COMPUTED TOMOGRAPHY;

BIOPSY; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84991217089     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2016.05.005     Document Type: Review

References (78)

1. [1] Carbone, P.P., Kaplan, H.S., Musshoff, K., et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 31 (1971), 1860–1861.
2. [2] Lister, T.A., Crowther, D., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin disease: Cotswolds meeting. J Clin Oncol 7:11 (1989), 1630–1636.
3. [3] Kaplan, H.S., Contiguity and progression in Hodgkin's disease. Cancer Res 31 (1971), 1811–1813.
4. [4] Castellino, R.A., Hoppe, R.T., et al. Computed tomography, lymphography, and staging laparotomy: correlations in initial staging of Hodgkin disease. AJR 143:7 (1984), 37–41.
5. [5] Gospadorowitz MK, O'Sullivan B, Koh ES. Prognostic factors: principles and applications. In: Prognostic factors in cancer. 3rd ed. Hoboken, NJ: Wiley-Liss; 2006:23-28.
6. [6] Diehl, V., Stein, H., Hummel, M., Zollinger, R., Connors, J.M., Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematol Am Soc Hematol Educ Program, 2003, 225–247.
7. [7] Moccia, A.A., Donaldson, J., et al. International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. J Clin Oncol 30 (2012), 3383–3388.
8. [8] Hasenclever, D., Diehl, V., A prognostic score for advanced Hodgkin's disease. N Engl J Med 339 (1998), 1506–1514.
9. [9] Hutchings, M., Loft, A., et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 91 (2006), 482–489.
10. [10] El-Galaly, T.C., d'Amore, F., et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography–staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 30 (2012), 4508–4514.
11. [11] Gerstner, E.R., Abrey, L.E., et al. CNS Hodgkin lymphoma. Blood 112:5 (2008), 1658–1661.
12. [12] Tassies, D., Sierra, J., Monserrat, E., Specific cutaneous involvement in Hodgkin's disease. Hematol Oncol 10:2 (1992), 75–79.
13. [13] Simon, S., Azevedxo, S.J., Byrnes, J.J., Erythema nodosum heralding recurrent Hodgkin's disease. Cancer 56:6 (1985), 1470–1472.
14. [14] Milionis, H.J., Elisaf, M.S., Psoriasiform lesions as paraneoplastic manifestation in Hodgkin's disease. Ann Oncol 9:4 (1998), 449–452.
15. [15] Ronchese, F., Gates, D.C., Ichthyosiform atrophy of the skin in Hodgkin's disease. N Engl J Med 255:6 (1956), 287–289.
16. [16] Ebstein, W., Das chronische Ruckfallsfieber, eine neue infektionskrankenheit. Berl Klin Wochenschr, 24, 1887, 565.
17. [17] Landgren, O., Pfeiffer, R.M., Kristinsson, S.Y., Survival patterns in patients with Hodgkin's Lymphoma with a pre-existing hospital discharge diagnosis of autoimmune disease. J Clin Oncol 28 (2010), 5081–5087.
18. [18] Meadows, L.M., Wendell, R.R., Moore, J.O., Hodgkin's disease presenting as myelofibrosis. Cancer 64 (1989), 1720–1726.
19. [19] Ward, E., DeSantis, C., Robbins, A., et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin, 64, 2014, 83.
20. [20] Nachman, J.B., Sposto, R., Herzog, P., et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol, 20, 2002, 3765.
21. [21] Englund, A., Hopstadius, C., Enblad, G., Hodgkin lymphoma—a survey of children and adolescents treated in Sweden 1985–2009. Acta Oncol 54 (2015), 41–48.
22. [22] Bazzeh, F., Rihani, R., Howard, S., Comparing adult and pediatric Hodgkin lymphoma in the Surveillance. Epidemiology and End Results program, 1988 – 2005: an analysis of 21 734 cases. Leuk Lymph 51 (2010), 2198–2207.
23. [23] Bjorkholm, M., Svedmyr, E., Sjoberg, J., How we treat elderly patients with Hodgkin lymphoma. Curr Opin Oncol 23 (2011), 421–428.
24. [24] Diepstra, A., van Imhoff, G.W., et al. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol 27 (2009), 3815–3821.
25. [25] Evens, A.M., Helenowski, I., Ramsdale, E., A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 119:3 (2012), 692–695.
26. [26] Jagadeesh, D., Diefenbach, C., Evens, A.M. X.I.I., Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes. Hematol Oncol 31:Suppl 1 (2013), 69–75.
27. [27] Kenis, C., Bron, D., et al. Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. Ann Oncol 24:5 (2013), 1306–1312.
28. [28] Stewart, H.L. Jr, Monto, R.W., Hodgkin's disease and pregnancy. Am J Obstet Gynecol 63 (1952), 570–578.
29. [29] Evens, A.M., Advani, R., et al. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol 31 (2013), 4132–4139.
30. [30] Jacobs, C., Donaldson, S.S., Rosenberg, S.A., Management of the pregnant patient with Hodgkin's disease. Ann Intern Med 95 (1981), 669–675.
31. [31] Gelb, A.B., van de Rijn, M., Warnke, R.A., Pregnancy-associated lymphomas. A clinicopathologic study. Cancer 78:2 (1996), 304–310.
32. [32] Yahalom, J., Treatment options for Hodgkin's disease during pregnancy. Leuk Lymphoma, 2, 1990, 151.
33. [33] Kanal, E., Barkovich, A.J., et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 188:6 (2007), 1447–1474.
34. [34] Lishner, M., Avivi, I., et al. Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting. J Clin Oncol 34 (2016), 501–508.
35. [35] Zanotti-Fregonara, P., Jan, S., et al. Absorbed 18F-FDG dose to the fetus during early pregnancy. J Nucl Med 51:5 (2010), 803–805.
36. [36] Cheson, B.D., Fisher, R.I., et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:27 (2014), 3059–3068.
37. [37] Barrington, S.F., Mikhaeel, N.G., et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32:27 (2014), 3048–3058.
38. [38] Hutchings, M., Loft, A., El Galaly, T.C., PET scan in Hodgkin lymphoma staging. Gallamini, A., (eds.) PET scan in Hodgkin lymphoma. Role in diagnosis, prognosis and treatment, 2016, Springer, Heidelberg, Germany.
39. [39] Hutchings, M., Loft, A., et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 91:4 (2006), 482–489.
40. [40] Bednaruk-Mlynski, E., Pienkowska, J., et al. Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma. Leuk Lymphoma 56:2 (2014), 377–382.
41. [41] El Galaly, T.C., Hutchings, M., et al. Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement. Leuk Lymphoma 55:10 (2014), 2349–2355.
42. [42] Hutchings, M., How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?. ASH Education Program Book 1 (2012), 322–327.
43. [43] Girinsky, T., van der Maazen, R., et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79:3 (2006), 270–277.
44. [44] Chiaravalloti, A., Danieli, R., et al. Initial staging of Hodgkins disease: role of contrast-enhanced 18F FDG PET/CT. Medicine, 93(8), 2014.
45. [45] Chalaye, J., Luciani, A., et al. Clinical impact of contrast-enhanced computed tomography combined with low-dose 18F-fluorodeoxyglucose positron emission tomography/computed tomography on routine lymphoma patient management. Leuk Lymphoma 55:12 (2014), 2887–2892.
46. [46] Vriens, D., Visser, E., de Geus-Oei, L.-F., Methodological considerations in quantification of oncological FDG PET studies. Eur J Nucl Med Mol Imaging 37:7 (2010), 1408–1425.
47. [47] Berthelsen, A.K., Holm, S., Loft, A., PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 32:10 (2005), 1167–1175.
48. [48] Specht, L., Yahalom, J., et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 89:4 (2014), 854–862.
49. [49] Weiler-Sagie, M., Kagna, O., Dann, E., Characterizing bone marrow involvement in Hodgkin's lymphoma by FDG-PET/CT. Eur J Nucl Med Mol Imaging 41:6 (2014), 1133–1140.
50. [50] Chen-Liang, T.H., Martin-Santos, T., et al. The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. Accuracy in a multicenter series of 372 patients. Am J Hematol 90:8 (2015), 686–690.
51. [51] Levis, A., Pietrasanta, D., et al. A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma. Clin Lymphoma 5:1 (2004), 50–55.
52. [52] Brunning, R.D., Bloomfield, C.D., McKenna, R.W., Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. Ann Intern Med 82:3 (1975), 365–366.
53. [53] Purz, S., Mauz-Karholz, C., et al. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. J Clin Oncol 29:26 (2011), 3523–3528.
54. [54] Adams, H.J.A., Kwee, T.C., Fijnheer, R., Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance. Eur J Haematol 95:1 (2015), 83–89.
55. [55] Albano, D., Patti, C., La Grutta, L., et al. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas. Eur J Radiol 85:2 (2016), 313–318.
56. [56] Moskowitz, C.H., Schöder, H., Teruya-Feldstein, J., Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 28 (2010), 1896–1903.
57. [57] Pregno, P., Chiappella, A., et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 119 (2012), 2066–2073.
58. [58] Cashen, A.F., Dehdashti, F., Luo, J., 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med 52 (2011), 386–392.
59. [59] Ceriani, L., Suriano, S., Ruberto, T., 18 F-FDG uptake changes in liver and mediastinum during chemotherapy in patients with diffuse large B-cell lymphoma. Clin Nucl Med 37 (2012), 949–952.
60. [60] Groheux, D., Delord, M., et al. Variation of liver SUV on (18)FDG-PET/CT studies in women with breast cancer. Clin Nucl Med 38 (2013), 422–425.
61. [61] Rubello, D., Gordien, P., et al. Variability of hepatic 18F-FDG uptake at interim PET in patients with Hodgkin lymphoma. Clin Nucl Med 40 (2015), e405–e410.
62. [62] Gagne, J.J., Thompson, L., O'Keefe, K., et al. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ, 349, 2014, g6802.
63. [63] Boellaard, R., O'Doherty, M.J., et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37 (2010), 181–200.
64. [64] Makris, N.E., Huisman, M.C., Kinahan, P.E., Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures. Eur J Nucl Med Mol Imaging 40 (2013), 1507–1515.
65. [65] Boellaard, R., Delgado-Bolton, R., et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42 (2015), 328–354.
66. [66] Larson, S.M., Erdi, Y., et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG Imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 2 (1999), 159–171.
67. [67] Bradley, A.J., Carrington, B.M., Lawrance, J.A., Assessment and significance of mediastinal bulk in Hodgkin's disease: comparison between computed tomography and chest radiography. J Clin Oncol 17 (1999), 2493–2498.
68. [68] Gobbi, P.G., Ghirardelli, M.L., et al. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. J Clin Oncol 19 (2001), 1388–1394.
69. [69] Gobbi, P.G., Broglia, C., et al. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. Cancer 101 (2004), 1824–1834.
70. [70] Song, M.K., Chung, J.S., et al. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma. Cancer Sci 104 (2013), 1656–1661.
71. [71] Kanoun, S., Rossi, C., et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 41 (2014), 1735–1743.
72. [72] Tseng, D., Rachakonda, L.P., et al. Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease. Radiat Oncol, 7, 2012, 5.
73. [73] Hutchings, M., Kostakoglu, L., et al. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. J Clin Oncol 32 (2014), 2705–2711.
74. [74] Punwani, S., Prakash, V., et al. Quantitative diffusion weighted MRI: a functional biomarker of nodal disease in Hodgkin lymphoma?. Cancer Biomark 7:4 (2010), 249–259.
75. [75] de Jong, A., Kwee, T.C., et al. Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma. Am J Nucl Med Mol Imaging 4 (2014), 231–238.
76. [76] Shields, A.F., Grierson, J.R., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:11 (1998), 1334–1336.
77. [77] Buchmann, I., Neumaier, B., [18F]3’-deoxy-3’-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations—a pilot study. Cancer Biother Radiopharm 19:4 (2004), 436–442.
78. [78] Buck, A.K., Bommer, M., et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res 66:22 (2006), 11055–11061.